Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 3/2009

01-03-2009 | Review

Bariatric Surgery, Safety and Type 2 Diabetes

Authors: Elias Spanakis, Claudia Gragnoli

Published in: Obesity Surgery | Issue 3/2009

Login to get access

Abstract

Obesity and type 2 diabetes (T2D) represent major health concerns in the USA. Weight loss is the most important aspect in T2D management, as it reduces both morbidity and mortality. Available lifestyle, behavioral, and pharmacological strategies provide just mild to moderate weight loss. The greatest degree of T2D prevention or T2D amelioration in obese subjects has been reported in subjects who underwent bariatric surgery. In the current review, we will describe various types of bariatric surgery, related safety profiles, and their effect on T2D, as well as the potential mechanisms involved in the remission of T2D. Finally, we hereby examine whether bariatric surgery may be considered a treatment for T2D in pregnant women, children, adolescents and subjects at least 65 years old.
Literature
1.
Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24(11):1936–40, Nov.CrossRefPubMed
2.
Zimmet P, Shaw J, Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003;20(9):693–702, Sep.CrossRefPubMed
3.
Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987;10(5):563–6, Sep–Oct.CrossRefPubMed
4.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351(26):2683–93, Dec 23.CrossRefPubMed
5.
NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991;115(12):956–61, Dec 15.CrossRef
6.
Halverson JD, Wise L, Wazna MF, et al. Jejunoileal bypass for morbid obesity. A critical appraisal. Am J Med 1978;64(3):461–75, Mar.CrossRefPubMed
7.
Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119(3):261–8, Mar.CrossRefPubMed
8.
9.
Suter M, Jayet C, Jayet A. Vertical banded gastroplasty: long-term results comparing three different techniques. Obes Surg 2000;10(1):41–6, Feb; discussion 7.CrossRefPubMed
10.
Tretbar LL, Taylor TL, Sifers EC. Weight reduction. Gastric plication for morbid obesity. J Kans Med Soc 1976;77(11):488–90, Nov.PubMed
11.
Kuzmak LI, Thelmo W, Abramson DL, et al. Reversible adjustable gastric banding. Surgical technique. Eur J Surg Acta Chir 1994;160(10):569–71, Oct.
12.
Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998;8(3):267–82, Jun.CrossRefPubMed
13.
14.
15.
16.
17.
Santoro S, Malzoni CE, Velhote MC, et al. Digestive adaptation with intestinal reserve: a neuroendocrine-based operation for morbid obesity. Obes Surg 2006;16(10):1371–9, Oct.CrossRefPubMed
18.
Santoro S, Velhote MC, Malzoni CE, et al. Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution. Sao Paulo Med J 2006;124(4):192–7, Jul 6.CrossRefPubMed
19.
Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk super-obese patient. Obes Surg 2004;14(4):492–7, Apr.CrossRefPubMed
20.
Miller K, Hoeller E, Aigner F. The implantable gastric stimulator for obesity: An update of the european experience in the LOSS (Laparoscopic Obesity Stimulation Survey) study. Treat Endocrinol 2006;5(1):53–8.CrossRefPubMed
21.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg 2004;14(7):991–8, Aug.CrossRefPubMed
22.
Regan JP, Inabnet WB, Gagner M, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 2003;13(6):861–4, Dec.CrossRefPubMed
23.
Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg 2004;14(5):671–6, May.CrossRefPubMed
24.
Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142(7):547–59, Apr 5.CrossRefPubMed
25.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. Jama 2004;292(14):1724–37, Oct 13.CrossRefPubMed
26.
Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299(3):316–23, Jan 23.CrossRefPubMed
27.
Dixon AF, Dixon JB, O'Brien PE. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005;90(2):813–9, Feb.CrossRefPubMed
28.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346(21):1623–30, May 23.CrossRefPubMed
29.
Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656–60, Dec 9.CrossRefPubMed
30.
Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000;141(11):4255–61, Nov.CrossRefPubMed
31.
Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90(1):359–65, Jan.CrossRefPubMed
32.
33.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238(4):467–84, Oct; discussion 84–5.PubMedPubMedCentral
34.
Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353(3):249–54, Jul 21.CrossRefPubMed
35.
Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005;48(11):2236–40, Nov.CrossRefPubMed
36.
Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48(12):2270–6, Dec.CrossRefPubMed
37.
le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243(1):108–14, Jan.CrossRefPubMedPubMedCentral
38.
Greenberg I, Perna F, Kaplan M, et al. Behavioral and psychological factors in the assessment and treatment of obesity surgery patients. Obes Res 2005;13(2):244–9, Feb.CrossRefPubMed
39.
Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232(4):515–29, Oct.CrossRefPubMedPubMedCentral
40.
Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3–60 month follow-up. Obes Surg 2000;10(3):233–9, Jun.CrossRefPubMed
41.
Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001;234(3):279–89, Sep; discussion 89–91.CrossRefPubMedPubMedCentral
42.
Westling A, Gustavsson S. Laparoscopic vs open Roux-en-Y gastric bypass: a prospective, randomized trial. Obes Surg 2001;11(3):284–92, Jun.CrossRefPubMed
43.
44.
Martin LF, Finigan KM, Nolan TE. Pregnancy after adjustable gastric banding. Obstet Gynecol 2000;95(6 Pt 1):927–30, Jun.PubMed
45.
Marceau P, Kaufman D, Biron S, et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 2004;14(3):318–24, Mar.CrossRefPubMed
46.
Dixon JB, Dixon ME, O'Brien PE. Birth outcomes in obese women after laparoscopic adjustable gastric banding. Obstet Gynecol 2005;106(5 Pt 1):965–72, Nov.CrossRefPubMed
47.
Skull AJ, Slater GH, Duncombe JE, et al. Laparoscopic adjustable banding in pregnancy: safety, patient tolerance and effect on obesity-related pregnancy outcomes. Obes Surg 2004;14(2):230–5, Feb.CrossRefPubMed
48.
ACOG Committee Opinion number 315, September 2005. Obesity in pregnancy. Obstet Gynecol 2005;106(3):671–5, Sep.CrossRef
49.
Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295(13):1549–55, Apr 5.CrossRefPubMed
50.
Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346(11):802–10, Mar 14.CrossRefPubMed
51.
Lawson ML, Kirk S, Mitchell T, et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: a multicenter study from the Pediatric Bariatric Study Group. J Pediatr Surg 2006;41(1):137–43, Jan; discussion -43.CrossRefPubMed
52.
Tsai WS, Inge TH, Burd RS. Bariatric surgery in adolescents: recent national trends in use and in-hospital outcome. Arch Pediatr Adolesc Med 2007;161(3):217–21, Mar.CrossRefPubMed
53.
Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 2004;114(1):217–23, Jul.CrossRefPubMed
54.
55.
56.
Sosa JL, Pombo H, Pallavicini H, et al. Laparoscopic gastric bypass beyond age 60. Obes Surg 2004;14(10):1398–401, Nov–Dec.CrossRefPubMed
57.
58.
Abu-Abeid S, Keidar A, Szold A. Resolution of chronic medical conditions after laparoscopic adjustable silicone gastric banding for the treatment of morbid obesity in the elderly. Surg Endosc 2001;15(2):132–4, Feb.CrossRefPubMed
59.
Varela JE, Wilson SE, Nguyen NT. Outcomes of bariatric surgery in the elderly. Am Surg 2006;72(10):865–9, Oct.PubMed
60.
Flum DR, Salem L, Elrod JA, et al. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA 2005;294(15):1903–8, Oct 19.CrossRefPubMed
Metadata
Title
Bariatric Surgery, Safety and Type 2 Diabetes
Authors
Elias Spanakis
Claudia Gragnoli
Publication date
01-03-2009
Publisher
Springer New York
Published in
Obesity Surgery / Issue 3/2009
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-008-9687-4

Other articles of this Issue 3/2009

Obesity Surgery 3/2009 Go to the issue

Research Article

Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2 (LBMI)

Research Article

Increase of Osteopontin Plasma Concentrations After Bariatric Surgery Independent from Inflammation and Insulin Resistance

Research Article

Changes in lipid profile and insulin resistance in obese patients after Scopinaro biliopancreatic diversion

Review

Psychosocial Evaluation for Bariatric Surgery: The Boston Interview and Opportunities for Intervention

Research Article

Gastric Bypass and Cardiac Autonomic Activity: Influence of Gender and Age

Case Report

Gastric Perforation and Death after the Insertion of an Intragastric Balloon